200 related articles for article (PubMed ID: 18552900)
1. [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support].
Schjesvold FH; Sjo M; Tangen JM; Hammerstrøm J; Brinch L
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1392-6. PubMed ID: 18552900
[TBL] [Abstract][Full Text] [Related]
2. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
3. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of amyloidosis].
Wien TN
Tidsskr Nor Laegeforen; 2008 Jun; 128(12):1397-400. PubMed ID: 18552901
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
Perfetti V; Siena S; Palladini G; Bregni M; Di Nicola M; Obici L; Magni M; Brunetti L; Gianni AM; Merlini G
Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
[TBL] [Abstract][Full Text] [Related]
6. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
7. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
9. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
10. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
Frossard V; Ketterer N; Rosselet A; Meier P; Cairoli A; Duchosal MA; Kovacsovics T
Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
[TBL] [Abstract][Full Text] [Related]
11. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
12. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
13. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
[TBL] [Abstract][Full Text] [Related]
14. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
Chow LQ; Bahlis N; Russell J; Chaudhry A; Morris D; Brown C; Stewart DA
Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
[TBL] [Abstract][Full Text] [Related]
15. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
[TBL] [Abstract][Full Text] [Related]
16. Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate.
Gertz MA; Lacy MQ; Dispenzieri A; Ansell SM; Elliott MA; Gastineau DA; Inwards DJ; Micallef IN; Porrata LF; Tefferi A; Litzow MR
Bone Marrow Transplant; 2004 Dec; 34(12):1025-31. PubMed ID: 15516945
[TBL] [Abstract][Full Text] [Related]
17. AL amyloidosis associated with B-cell lymphoproliferative disorders: frequency and treatment outcomes.
Sanchorawala V; Blanchard E; Seldin DC; O'Hara C; Skinner M; Wright DG
Am J Hematol; 2006 Sep; 81(9):692-5. PubMed ID: 16795060
[TBL] [Abstract][Full Text] [Related]
18. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
[TBL] [Abstract][Full Text] [Related]
19. [High-dose treatment with autologous stem cell support in a Norwegian region].
Hammerstrøm J; Aasland IL; Telhaug R; Moen T; Lødemel B; Sørum Y; Brudevold R; Herlofsen O; Sørbø JH; Almvik T; Lamvik J
Tidsskr Nor Laegeforen; 2004 Oct; 124(19):2498-500. PubMed ID: 15477890
[TBL] [Abstract][Full Text] [Related]
20. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
Comenzo RL; Vosburgh E; Falk RH; Sanchorawala V; Reisinger J; Dubrey S; Dember LM; Berk JL; Akpek G; LaValley M; O'hara C; Arkin CF; Wright DG; Skinner M
Blood; 1998 May; 91(10):3662-70. PubMed ID: 9573002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
